Alnylam Posts Q4 Loss as R&D Spending Offsets Revenue Jump, Offers New Details on Alliances | GenomeWeb

Alnylam Pharmaceuticals this week reported a loss for the fourth quarter as growing operating costs, primarily related to its research and development activities, more than offset a strong increase in revenues.

Still, officials said the company remains well-positioned to weather the financial storm battering many of its peers in the biotechnology sector.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.